文献速递泌尿生殖与妇科肿瘤放疗

低剂量率近距离放疗与冷冻治疗在低中危前列腺癌中的比较

Low-Dose-Rate Brachytherapy Versus Cryotherapy in Low- and Intermediate-Risk Prostate Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-01-16

该回顾性研究分析了1990至2012年在本机构治疗的359例低至中危前列腺癌患者,比较低剂量率近距离放疗与冷冻治疗的生化控制效果。结果显示冷冻治疗组5年生化无进展生存率显著低于近距离放疗组(57.9% vs 89.6%,P<.0001),低危和中危亚组均存在显著差异。作者认为冷冻治疗劣于近距离放疗,不推荐作为该患者子集的一线局部治疗。

要点

  • 冷冻治疗组5年bPFS为57.9%,近距离放疗组为89.6%,差异显著(P<.0001)。
  • 低危和中危亚组中,近距离放疗的bPFS均显著优于冷冻治疗(P<.05)。
  • 冷冻治疗的中位冻融周期为2次,平均最低温度为-35°C。

核心结论

  • 对于低至中危前列腺癌患者,冷冻治疗的生化控制效果劣于低剂量率近距离放疗。
  • 冷冻治疗不推荐作为该患者子集的一线局部治疗。

研究设计与样本

  • 单机构回顾性图表审查,纳入1990至2012年连续治疗的低至中危前列腺癌患者。
  • 共分析359例患者:低危冷冻治疗50例,中危冷冻治疗92例,低危近距离放疗133例,中危近距离放疗84例。
  • 失败定义为前列腺特异性抗原最低点+2 ng/mL。

主要发现

  • 冷冻治疗组5年生化无进展生存率为57.9%,近距离放疗组为89.6%(P<.0001)。
  • 5年bPFS率分别为:低危冷冻治疗70.0%,中危冷冻治疗51.4%,低危近距离放疗89.4%,中危近距离放疗89.7%。
  • 低危和中危组中,近距离放疗与冷冻治疗的bPFS率差异均显著(P<.05)。
  • 冷冻治疗患者平均最低温度为-35°C(范围-96°C至-6°C),中位冻融周期为2次(范围2-4次)。

临床怎么用

  • 对于低至中危前列腺癌,优先考虑低剂量率近距离放疗作为局部治疗选择。
  • 冷冻治疗不宜作为该患者子集的首选局部治疗。

局限性

  • 本研究为单机构回顾性研究,可能存在选择偏倚。
  • 冷冻治疗组与近距离放疗组的随访时间不同,可能影响结果比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Cryotherapy and brachytherapy are definitive local treatment options for low- to intermediate-risk prostate cancer. There are both prospective and retrospective data for brachytherapy, but the use of cryotherapy has been limited primarily to single-institution retrospective studies. Currently, no published evidence has compared low-dose-rate brachytherapy versus cryotherapy. METHODS AND MATERIALS: Institutional review board approval was obtained to conduct a retrospective chart review of consecutive patients treated at our institution from 1990 to 2012. For inclusion, patients must have received a prostate cancer diagnosis and have been considered to have low- to intermediate-risk disease according to the National Comprehensive Cancer Network criteria. All patients received brachytherapy or cryotherapy treatment. Disease specifics and failure details were collected for all patients. Failure was defined as prostate-specific antigen nadir +2 ng/mL. RESULTS: A total of 359 patients were analyzed. The groups comprised 50 low-risk cryotherapy (LRC), 92 intermediate-risk cryotherapy (IRC), 133 low-risk brachytherapy (LRB), and 84 intermediate-risk brachytherapy (IRB) patients. The median prostate-specific antigen follow-up periods were 85.6 months (LRC), 59.2 months (IRC), 74.9 months (LRB), and 59.8 months (IRB). The 5-year biochemical progression-free survival (bPFS) rate was 57.9% in the cryotherapy group versus 89.6% in the brachytherapy group (P<.0001). The 5-year bPFS rate was 70.0% (LRC), 51.4% (IRC), 89.4% (LRB), and 89.7% (IRB). The bPFS rate was significantly different between brachytherapy and cryotherapy for low- and intermediate-risk groups (P<.05). The mean nadir temperature reached for cryotherapy patients was -35°C (range, -96°C to -6°C). Cryotherapy used a median of 2 freeze-thaw cycles (range, 2-4 freeze-thaw cycles). CONCLUSIONS: Results from this study suggest that cryotherapy is inferior to brachytherapy for patients with low- to intermediate-risk prostate cancer. Patient selection criteria for consideration of cryotherapy and brachytherapy are similar in terms of anesthesia candidacy. Therefore, cryotherapy would not be recommended as a first-line local therapy for this particular patient subset.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Gestaut MM, Cai W, Vyas S, et al. Low-Dose-Rate Brachytherapy Versus Cryotherapy in Low- and Intermediate-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2017. PMID: 28586945. doi:10.1016/j.ijrobp.2017.01.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。